Fisher & Paykel Healthcare shares advanced on Friday, with Australian trading at a record A$36.59, after the company raised its full-year revenue and profit guidance for fiscal 2027.
The New Zealand-based medical device manufacturer now expects operating revenue between NZ$2.47 billion and NZ$2.57 billion for the year ending March 2027, up from prior guidance. Net profit after tax is projected between NZ$525 million and NZ$565 million, also revised upward from previous estimates.
First-half fiscal 2027 net profit is forecast at approximately NZ$280 million. The company attributed the improved outlook to strong demand for its Hospital product group, including new hardware devices and consumables. Management cited shifts in clinical practice as a key driver of consumable sales growth.
CEO Lewis Gradon highlighted ongoing continuous improvement initiatives that have enhanced gross margins and operating efficiencies. The profit outlook was further supported by the inclusion of NZ$23 million in refunds related to the U.S. International Emergency Economic Powers Act (IEEPA) tariffs, providing a near-term earnings boost.
Australian shares of Fisher & Paykel rose 1.8% to a record high, while New Zealand shares gained more than 1%, both reaching record levels as investors reacted to the upgraded guidance.
